Boston Scientific CRM audit
This article was originally published in The Gray Sheet
Executive Summary
Firm anticipates FDA inspections of cardiac rhythm management facilities impacted by a December 2005 warning letter to Guidant to begin in the "coming weeks," CEO Jim Tobin said Oct. 18 during the firm's third-quarter earnings call (1"The Gray Sheet" Jan. 2, 2006, p. 3). The company is "ready," he says...
You may also be interested in...
Guidant Shareholders To Vote On J&J Offer; Boston Scientific Still Interested
Guidant's board of directors has formally endorsed Johnson & Johnson's $21.5 bil. takeover bid while simultaneously agreeing to enter into discussions with Boston Scientific on its $25 bil. competing offer
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: